# S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

> **NCT03499808** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 43 (actual)

## Conditions studied

- Amorphous, Eosinophilic, and Acellular Deposit
- Constipation
- Diarrhea
- Early Satiety
- Gastrointestinal Hemorrhage
- Hepatomegaly
- Lymphadenopathy
- Macroglossia
- Nausea
- Primary Systemic Amyloidosis
- Purpura
- Recurrent Primary Amyloidosis
- Refractory Primary Amyloidosis

## Interventions

- **BIOLOGICAL:** Isatuximab
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT03499808
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-06
- **Primary completion:** 2023-08-30
- **Final completion:** 2023-09-19
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03499808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03499808, "S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03499808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*